New study probes why diabetes patients develop fatty liver
NCT ID NCT07246421
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the hormone glucagon works in people with type 2 diabetes, with or without fatty liver disease. Researchers will give participants low and high doses of glucagon and use scans and blood tests to measure how the liver and heart respond. The goal is to understand if glucagon resistance contributes to liver fat buildup and heart problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Glucagon infusion
What this could lead to
If successful, this study could reveal why some people with type 2 diabetes develop fatty liver and heart problems, pointing toward new treatment targets.
What could go wrong
This is a small, early-stage observational study with only 24 participants, so results may not apply to everyone. It is designed to gather knowledge, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC ASSOCIATED FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
RECRUITINGAarhus, 8000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••